- Home
- Personal stories
Personal stories
What is metastatic cancer?
The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.
Johnson & Johnson named a 2025 Fortune World’s Most Admired Company
A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.
What you need to know about Johnson & Johnson’s 2024 fourth-quarter and full-year earnings report
Check out this infographic breakdown of the company’s fourth-quarter and full-year performance, with highlights from its Innovative Medicine and MedTech businesses.
5 things we now know about eczema (a.k.a., atopic dermatitis)
The most common inflammatory skin disease causes scaly patches, blisters and severe itching, but it’s far more than just a cosmetic concern. Learn why Johnson & Johnson is focused on helping the millions living with this painful condition.
Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools
Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.
What is lupus?
Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.
Johnson & Johnson Supports and Celebrates the Middlesex College/Hackensack Meridian Health Nursing Program’s Class of 2024
J&J provides annual scholarships to the program to elevate, empower, and advocate for the nursing profession.
Getting in front of cancer at the 66th American Society of Hematology (ASH) Annual Meeting
Andreas Gerber, Worldwide Vice President of Oncology, shares Johnson & Johnson’s bold ambition to get in front of cancer. Read about the company’s success in hematologic malignancies, new pivotal data at this year’s ASH Annual Meeting, and important key takeaways.